Ethanol-induction of Cytochrome P450 2A5: Permissive Role for CYP2E1

Yongke Lu, Jian Zhuge, Defeng Wu and Arthur I. Cederbaum

Department of Medicine, Division of Liver Diseases (YL); Department of Pathology (JZ); Department of Pharmacology and Systems Therapeutics (DW, AIC).

Mount Sinai School of Medicine
Box 1603
One Gustave L Levy Place
New York, NY 10029
RUNNING TITLE: Induction of CYP2A5 by Ethanol

Correspondence to:

Dr. Arthur I. Cederbaum

Department of Pharmacology and Systems Therapeutics

Mount Sinai School of Medicine

One Gustave L. Levy Place

New York, NY 10029

arthur.cederbaum@mssm.edu

Phone: 212-241-7285

Fax: 212—996-7214

The number of text pages is: 28

The number of figures are: 6

The number of References are: 40

The number of words in the Abstract are: 247

The number of words in the Introduction are: 655

The number of words in the Discussion are: 1331

Abbreviations: ALD, alcoholic liver disease; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; KO, knockout; KI, knockin; NAC, N-acetyl-cysteine; PNP, Para-nitrophenol; TBARs, thiobarbituric acid-reactive substances; Vc, vitamin C; WT, wild type
ABSTRACT

CYP2A5 metabolizes xenobiotics and activates hepatocarcinogens and induction occurs in response to hepatic damage and cellular stress. We evaluated if ethanol can elevate CYP2A5, and whether CYP2E1 plays a role in the ethanol induction of CYP2A5. Wild type (WT), CYP2E1 knockout (KO) and CYP2E1 knockin (KI) mice were fed ethanol for 3 weeks. Ethanol increased CYP2E1 and CYP2A5 protein and activity in WT mice but not in the KO mice. Induction of CYP2A5 (and CYP2E1) was restored in the KI mice. Ethanol induction of CYP2A5 occurred only after CYP2E1 was first induced.

Immunohistochemistry staining revealed that CYP2E1 and CYP2A5 co-localize to the same zones in the liver. Ethanol also elevated CYP2A5 mRNA levels in WT and KI mice but not in KO mice. Induction of CYP2A5 by cadmium was partially decreased in KO mice compared to WT or KI mice. Ethanol elevated CYP2A4 mRNA levels in all mice although the extent of induction was lowest in the KO mice. In summary, ethanol elevated mouse hepatic CYP2A5 levels which may be of toxicological significance since CYP2A5 metabolizes nicotine and other drugs and activates hepatocarcinogens. Induction of CYP2A5 by ethanol is potentiated by the induction of CYP2E1. We speculate that ethanol induction of CYP2E1 followed by increases of ROS and activation of Nrf2 are important steps in the mechanism by which ethanol induces CYP2A5. The possibility that induction of CYP2E1 is permissive for the induction of CYP2A5 may reflect a new contribution by CYP2E1 to the actions of ethanol.
INTRODUCTION

Mouse CYP2A5 and its human orthologue CYP2A6 metabolize several important xenobiotics including nicotine, coumarin, cotinine, testosterone, aflatoxin B1 and nitrosamines (Su and Ding, 2004). CYP2A5 is expressed in many tissues with high levels found in the respiratory tract, liver and kidney. Increased expression of CYP2A5 occurs during viral, fulminant or bacterial hepatitis, in certain tumors and following treatment with a variety of hepatotoxins and heavy metals (Jounaidi et al, 1994; Abu-Bakar et al, 2004; De-Oliveira et al, 2006; Lamsa et al, 2010). Induction of CYP2A5 has been suggested to occur in response to hepatocellular damage and to endoplasmic reticulum stress (Gilmore and Kirby, 2004). Depending on the inducer, the activation of hepatic CYP2A5 can occur via transcriptional and posttranscriptional mechanisms (Abu-Bakar et al, 2004; Gilmore and Kirby, 2004; Abu-Bakar et al, 2007). Pyrazole, widely used as an inhibitor of alcohol dehydrogenase and of ethanol metabolism (Goldberg and Rydberg, 1969), induces CYP2A5 largely by a post-transcriptional mechanism involving stabilization of the CYP2A5 mRNA (Juvonen et al, 1985; Nichols and Kirby, 2008). Recent studies have implicated a role for cellular redox status and possible activation of stress-related transcription factors in activation of CYP2A5 (Su and Ding, 2004; Gilmore and Kirby, 2004; Abu-Bakar et al, 2007; Lamsa et al, 2010). For example, treatment of hepatocytes with menadione, a redox cycling agent, elevated CYP2A5 expression (Gilmore and Kirby, 2004). Pyrazole increases oxidative stress; pretreatment of hepatocytes with antioxidants such as N-acetylcysteine or vitamine E blunted pyrazole-mediated increases in CYP2A5 mRNA levels (Gilmore and Kirby, 2004). In a mouse hepatitis model, high CYP2A5 expression was found to colocalize with superoxide formation suggesting that superoxide can upregulate CYP2A5 (Sipowicz et al, 1997). A major advance was the findings that CYP2A5 constitutive expression and induction by heavy metals such as cadmium or lead or mercury was dependent on the redox-sensitive transcription factor Nrf2 in liver (Abu-Bakar et al, 2004; Abu-Bakar et al, 2007; Lamsa et al, 2010). CYP2A5 was upregulated by Nrf2 overexpression or deregulated by overexpression of Keap 1, an inhibitor of Nrf2 translocation to the nucleus (Lamsa et al, 2010).
We previously found that chronic ethanol feeding to mice resulted in a two-fold increase in Nrf2 levels in the liver (Gong and Cederbaum, 2006). Ethanol has long been known to elevate CYP2E1 levels (Lieber and DeCarli, 1972; Lieber, 1999); the two fold increase by ethanol of Nrf2 levels was associated with a four-fold increase in CYP2E1 (Gong and Cederbaum, 2006). The potent inducer of CYP2A5, pyrazole, can also elevate CYP2E1 (Song et al, 1986; Yang et al, 1990; Winters and Cederbaum, 1992). Pyrazole treatment of mice or rats elevated Nrf2 levels about three-fold in association with a similar increase in CYP2E1 (Gong and Cederbaum, 2006). CYP2E1 plays an important role in ethanol-induced oxidative stress (Lu and Cederbaum, 2008; Cederbaum et al, 2009). Chronic ethanol treatment can elevate other CYPs besides CYP2E1, e.g. CYP2B (Johansson et al, 1988) or CYP3A (Niemela et al, 1998). Hepatic levels of CYP2E1, CYP2A6 and CYP 3A were elevated in patients with alcoholic and nonalcoholic liver diseases (Niemela et al, 2000). One study in which ethanol was administered in the drinking water (10% ethanol) for 2 weeks reported that ethanol did not elevate CYP2A5 in DBA mice although pyrazole treatment did (Honkakoski et al, 1988). However, ethanol induction of CYP2E1 was modest (Honkakoski et al, 1988) and steatosis is generally not significantly produced in ethanol in drinking water models. In the current study, we evaluated whether chronic ethanol administration in a liquid diet model which produces fatty liver and prominent induction of CYP2E1 can induce CYP2A5. Such a possible elevation would be important in view of the toxicologically significant substrates which CYP2A5 metabolizes e.g. nicotine, coumarin, aflatoxin B1, nitrosamines. One goal of the current study was to determine whether chronic ethanol consumption can elevate CYP2A5. The other goal was to evaluate whether ethanol induction of CYP2E1 plays a role in the ethanol induction of CYP2A5.
MATERIALS AND METHODS

Animals and Ethanol Treatment. SV129-background CYP2E1-knockout (Lee et al, 1996) and humanized CYP2E1 transgenic knockin mice (Cheung et al, 2005) were kindly provided by Dr. Frank J. Gonzalez (Laboratory of Metabolism, National Cancer Institute, Bethesda, MD), colonies were established at Mount Sinai and the female offspring of these mating pairs were used in this study. The female SV129 wild type mice were purchased from Charles River Laboratory. Depending on the strain, female mice express much higher levels of CYP2A4 as compared to male mice whereas CYP2A5 is highly expressed in both male and female mice (Honkakoski and Negishi, 1997; Su and Ding, 2004). All mice were housed in temperature-controlled animal facilities with 12-hour light/12-hour dark cycles and were permitted consumption of tap water and Purina standard chow ad libitum until being fed the liquid diets. The mice received humane care, and experiments were carried out according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals and with approval of the Mount Sinai Animal Care and Use Committee.

All mice were initially fed the control liquid dextrose diet (Bio-Serv, Frenchtown, NJ) for 3 days to acclimate them to the liquid diet. Afterward, the mice were fed either the liquid ethanol diet (Bio-Serv, Frenchtown, NJ) or the control liquid dextrose diet, as described by Lieber and DeCarli (Lieber and DeCarli, 1972) for 3 weeks. The content of ethanol was gradually increased every 3-4 days from 10% (1.77% [vol/vol]) of total calories to 20% (3.54% [vol/vol]), 25% (4.42% [vol/vol]), 30% (5.31% [vol/vol]), and finally 35% of total calories (6.2% [vol/vol]). For experiments involving 1 or 2 weeks of feeding (time course), the mice were directly subjected to the diet containing ethanol as 35% of total calories. The control mice were pair-fed the control dextrose diet on an iso-energetic basis. The ethanol-fed mice had access to their rations ad libitum, and the conditions of wild-type, knockout, and humanized transgenic mice were comparable. The amount of food consumed by CYP2E1-knockout mice, the knockin mice and the wild-type mice was approximately the same.
No mice died in any group after 3 weeks of feeding with the control or ethanol-containing diet. Before being sacrificed, the mice were fasted overnight and body weight was measured. Blood was collected and serum was separated. As described in Lu et al. 2010, the ethanol feeding elevated serum transaminases, hepatic steatosis and oxidant stress in the CYP2E1 KI mice to a much greater extent than in the CYP2E1 KO mice. Whole liver was removed and liver weight measured; then the liver was rapidly excised into fragments and washed with cold saline and one aliquot of tissue was placed in 10% formalin solution for paraffin blocking. Another aliquot of tissue was placed in RNA later solution (Ambion) for RNA extraction. The remaining aliquots were stored at -80°C for further assays. Liver homogenates were prepared in ice-cold 0.15 M KCl and stored at -80°C in aliquots.

**Cadmium induction of CYP2A5** Cadmium Chloride was injected, once, IP at 3 mg/kg body weight, to WT, CYP2E1 KO and CYP2E1 KI mice. Before cadmium injection, some WT mice were injected with saline or vitamin C (Vc, 125 mg/kg, IP, twice per day for 3 days; on day 3 cadmium was injected 30 min after the Vc injection). Other WT mice were injected with N-acetyl-cysteine (NAC, 150 mg/kg, IP, once per day for 3 days; on day 3 cadmium was injected 30 min after the NAC injection). Mice were killed 18 h after the cadmium injection.

**Immunohistochemical staining** for CYP2E1 was performed by using anti-CYP2E1 antibody (a gift from Dr. Jerome Lasker, Hackensack Biomedical Research Institute, Hackensack, NJ) followed by an IHC Select® HRP/DAB kit. Immunohistochemical staining for CYP2A5 was performed by using anti-CYP2A5 (a gift from Dr. Risto Juvonen, Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland) followed by a Broad Spectrum (AEC) Histostain Plus kit (Invitrogen). No staining was observed in the absence of the primary antibody, either anti-CYP2E1 IgG or anti-CYP2A5 IgG.

**Preparation of hepatic microsomes.** Hepatic microsomes were prepared by placing liver aliquots in 0.15 M KCl and homogenized in a polytron homogenizer for 10 strokes. The homogenate was centrifuged at
9,000 g for 20 min, and then the resulting supernatant fraction was centrifuged further at 105,000 g for 60 min. The resulting pellets (microsomes) were resuspended in 50 mM sodium phosphate buffer (pH 7.4). All procedures were carried out under cold conditions.

**Cytochrome P450 2E1 and 2A5 Activity.** CYP2E1 activity was measured by the rate of oxidation of 1 mM p-nitrophenol to p-nitrocatechol by 100 μg of microsomal protein for 15 min at 37 °C (Lu and Cederbaum, 2006). CYP2A5 activity was measured by assessing coumarin 7-hydroxylase activity with 100 μM coumarin as substrate plus 100 μg of microsomal protein and incubation for 15 min at 37 °C (Lu and Cederbaum, 2006).

**Western Blotting.** Hepatic proteins in liver homogenates were separated by SDS-PAGE and transferred to nitrocellulose membranes. After 1 h of blocking with 2% fat-free milk, membranes were then incubated for overnight with CYP2E1, CYP2A5 and β-actin (Santa Cruz) antibodies followed by 1 h incubation with peroxidase secondary anti-rabbit, anti-chick and anti-goat (Millipore), respectively. Chemiluminescence was detected by Image Reader LAS-4000 (Fijifilm) after adding of Pierce EC Western Blotting Substrate (Thermo Scientific). β-Actin was used as a loading control. The bands of proteins were quantitated with the Automated Digitizing System (ImageJ gel programs, version 1.34S; National Institutes of Health).

**Reverse Transcription and Real-time qPCR Assay for the mRNA Levels of CYP2A5 and CYP2A4**

Total RNA from liver tissue was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. One μg of RNA sample was reverse transcribed to produce cDNA using random hexamer primers and ImProm-II reverse transcriptase (Promega, Madison, WI) according to the manufacturer's instructions. The primers were designed according to CYP2A5 (NM_007812.4) and CYP2A4 (NM_009997.2) mRNA sequences, which have 98% identity between them. The primers are located in exon 3 (Forward) and exon 4 (Reverse)
respectively. To increase the specificity, the 3’-end base is different between CYP2A5 and CYP2A4 (shown in lower case in the CYP2A4 primer sequences). Real-time quantitative PCR assay for the expression of CYP2A5 with cDNA and Lightcycler 480 SYBR green I Master (Roche Diagnostics GmbH, Mannheim, Germany) was carried out using the following primers: 

CYP2A5 (145 bp) FW: 5′-TCGGAAGACGAACGGTGCTTTT-3′ (505-526) and RV 5′-GCTTCCAGCATCATTCGAAGC-3′ (649-628); CYP2A4 (147 bp) FW: 5′-CGGAAGACGAACGGTGCTTTc-3′ (507-527), and RV: 5′-GAgGCTTCCAGCATCATTCtAACa-3′ (653-629) in a LightCycler 480 system (Roche). The protocol for real-time PCR was: activation of polymerase at 95°C for 10 min, then 95°C for 10 s, 55°C for 20 s and 72°C for 20 s for 50 cycles. All real-time PCR products were applied by melting curve analysis. The mRNA levels of CYP2A5 and CYP2A4 were normalized against the GAPDH control levels using the comparative Cₜ (ΔΔCₜ) method (Livak and Schmittgen, 2001).

Statistics Results are expressed as means ± SEMs. Statistical evaluation was carried out by one-way ANOVA followed by the Student-Newman-Keuls post hoc test. P values of less than 0.05 were considered statistically significant. The number of experiments is indicated in the legends to figures.
Results

Levels of CYP2E1 and CYP2A5 in wild type, CYP2E1 knockout and CYP2E1 knockin mice

To evaluate biochemical and toxicological actions of CYP2E1, Gonzalez and colleagues have established CYP2E1 knockout (KO) mice and CYP2E1 knockin (KI) mice, in which the human CYP2E1 has been introduced into the CYP2E1 KO mice (Lee et al, 1996; Cheung et al, 2005). The latter allows studies on the effects of human CYP2E1 in vivo in the absence of the mouse CYP2E1 (Cheung et al, 2005).

Pyrazole, an inducer of CYP2E1, can also induce CYP2A5 (Juvonen et al, 1985; Nichols and Kirby, 2008). We initiated studies to evaluate whether CYP2E1 and CYP2A5 levels and induction are associated with each other. Figure 1 shows the levels of CYP2E1 in WT mice, CYP2E1 KO mice, and CYP2E1 KI mice. CYP2E1 was absent in the KO mice and present at high levels in the KI mice as compared to the WT mice. The antibody used to detect CYP2A cannot distinguish between CYP2A4 and CYP2A5, both of which are present in female mice, and immunoblots detected two bands in livers of female wild type control mice and CYP2E1 KI mice (Fig 1). The upper band was barely detectable in livers from control male mice but was present in livers from female control mice (data not shown). The bottom band was present in high levels in livers of both male and female mice (data not shown). Since CYP2A5 is present in livers from male and female mice whereas CYP2A4 is very low or barely detectable in livers from male mice, the top band in the immunoblots for CYP2A is likely to be CYP2A4 while the bottom band is likely to be CYP2A5. Basal levels of CYP2A5 followed a similar pattern as the basal levels of CYP2E1, lowest in the CYP2E1 KO mice, intermediate in the WT mice and highest in the CYP2E1 KI mice (Fig 1). CYP2A5 was present in the absence of CYP2E1, but highest levels of CYP2A5 expression occurs when CYP2E1 is highly expressed. The top band in the immunoblots, presumably CYP2A4 was also present in highest levels in the CYP2E1 KI mice, and barely detectable in the CYP2E1 KO mice (Fig 1).
Induction of CYP2A5 by Chronic Ethanol Administration

Since chronic ethanol feeding elevates CYP2E1, we evaluated whether ethanol also induces CYP2A5 and if it does, whether there was an association between induction of CYP2E1 and CYP2A5. Figure 2B shows that after 3 weeks of ethanol administration, levels of CYP2E1 were increased 2.4-fold by ethanol in WT (WE) mice as compared to the dextrose-fed (WD) controls. Levels of CYP2A5 were also increased by ethanol in the WT mice (4.4-fold). However, ethanol did not significantly elevate CYP2A5 in the CYP2E1 KO mice (Fig 2B). Oxidation of p-nitrophenol (PNP) and 7-hydroxylation of coumarin were assayed as reflections of CYP2E1 and CYP2A5 catalytic activities, respectively. The chronic ethanol treatment elevated PNP oxidation by about 3-fold in the WT mice: PNP oxidation was very low and not elevated by ethanol in the CYP2E1 KO mice (Fig 2A). Coumarin 7-hydroxylase activity was increased about 6-fold by ethanol in the WT mice, but no significant increase was observed in the CYP2E1 KO mice (Fig 2A).

Ethanol Induction of CYP2A5 is Restored in CYP2E1 KI Mice

If the poor ability of ethanol to induce CYP2A5 in CYP2E1 KO mice is due to the absence of CYP2E1, restoring CYP2E1 should restore induction of CYP2A5 by ethanol. CYP2E1 KI mice were fed ethanol or dextrose for 3 weeks. Levels of CYP2E1 protein and activity were elevated in the CYP2E1 KI mice fed ethanol as compared to the dextrose control (Fig 2A and B), and were even higher than the levels and activity of CYP2E1 in the ethanol-fed WT mice. Levels of CYP2A5 and activity of CYP2A5 were elevated by ethanol in the CYP2E1 KI mice as compared to the dextrose controls and, similar to CYP2E1, were even higher than the levels and activity of CYP2A5 in the ethanol-fed WT mice (Fig 2A and B). Thus, levels and activity of CYP2A5 after ethanol treatment mimic levels and activity of CYP2E1, both being low in CYP2E1 KO mice and both being high in CYP2E1 KI mice. Immunohistochemical staining showed that CYP2E1 and CYP2A5 co-localize to the same zones of the liver of the ethanol-fed KI mice.
such that areas of the liver where CYP2E1 is highly expressed are the areas where CYP2A5 is highly expressed (Fig 2C).

**Time course for Induction of CYP2E1 and CYP2A5 by Ethanol**

Since ethanol elevated both CYP2E1 and CYP2A5, and the ethanol elevation of CYP2A5 was blunted in the absence of CYP2E1 (CYP2E1 KO mice), we compared the time course for induction of the two CYPs by ethanol. Immunoblot analysis showed that CYP2E1 was elevated after one week of ethanol feeding and then slowly increased further after 2 and 3 weeks of ethanol feeding (Fig 3A). Similarly, CYP2E1 catalytic activity was also elevated after 1 week of ethanol feeding and slightly increased further at 2 and 3 weeks of ethanol feeding (Fig 3B). Levels and activity of CYP2A5 were not increased after 1 week of ethanol feeding but began to increase after 2, and especially after 3 weeks of the ethanol feeding (Fig 3 A and B). Thus, ethanol induction of CYP2E1 occurs prior to the ethanol induction of CYP2A5.

**Ethanol Elevates CYP2A5 (and CYP2A4) mRNA Levels**

The above studies show that chronic ethanol consumption elevates CYP2A5 protein levels and activity in WT mice and CYP2E1 KI mice, but not in CYP2E1 KO mice. We evaluated whether such increases in CYP2A5 by ethanol are associated with increases in CYP2A5 mRNA. Indeed, the CYP2A5 mRNA was elevated by ethanol in WT mice and CYP2E1 KI mice, but not in CYP2E1 KO mice (Fig 4 B). The increase in CYP2A5 mRNA was highest in the CYP2E1 KI mice fed ethanol, analogous to the high protein levels and activity of CYP2A5 in these mice. Ethanol did not elevate levels of CYP2E1 mRNA in the WT or the CYP2E1 KI mice (data not shown) confirming that ethanol induction of CYP2E1 is largely posttranscriptional (Song et al, 1986). Ethanol increased CYP2A4 mRNA levels in all 3 mouse genotypes (Fig 4 A). The increase in CYP2A4 mRNA in the CYP2E1 KO mice by ethanol does indicate that these mice are responsive to induction of at least some members of the CYP2A family e.g CYP2A4 but not CYP2A5.
Comparison of CYP2E1 and CYP2A6 Levels in Human Liver

Samples of human liver (no information on age, gender, medications, and possible polymorphisms was available) were obtained from the Department of Pathology at Mount Sinai Medical Center, and levels of CYP2E1 and CYP2A6 (the human orthologue of the mouse CYP2A5) were determined. The CYP2A5 antibody recognizes CYP2A6. Levels of CYP2E1 varied widely, being elevated in one of two patients with alcoholic liver disease and in two of four patients with cirrhosis (Fig 5). Interestingly, the levels of CYP2A6 varied widely as well but were reflective of the levels of CYP2E1 in that CYP2A6 was high in the one patient with alcoholic liver disease who displayed high CYP2E1 and in the two patients with cirrhosis who displayed elevated CYP2E1, but were low in those livers which displayed low CYP2E1 (Fig 5).

Cadmium induction of CYP2A5

The above results suggest that ethanol-induction of CYP2A5 is largely CYP2E1-dependent, as ethanol also induces CYP2E1. We evaluated whether other CYP2A5 inducers which do not induce CYP2E1 also induce CYP2A5 in a CYP2E1-dependent way. CYP2A5 can be induced by heavy metals; induction of CYP2A5 by cadmium was shown to be dependent on Nrf2 in liver (Abu-Bakar et al 2004; 2007; Lamsa et al 2010). The ability of cadmium to induce CYP2A5 was evaluated in WT, CYP2E1 KO and CYP2E1 KI mice, Fig 6A verifies that cadmium elevated CYP2A5 catalytic activity in SV129 male and female WT mice, under conditions in which it had no effect on CYP2E1 catalytic activity (Fig 6A). To evaluate if ROS is important for the elevated induction of CYP2A5 found in the presence of cadmium plus basal level of CYP2E1, the effect of two antioxidants on the induction of CYP2A5 by cadmium in WT mice was determined. Results in Fig 6B shows that administration of vitamin C or N-acetylcysteine to cadmium treated WT mice blunted the elevation of CYP2A5 activity and content. The two antioxidants had no effect on the activity of CYP2E1 (Fig 6B).
Unlike ethanol, cadmium treatment increased CYP2A5 catalytic activity in CYP2E1 KO mice (Fig 6C). The cadmium-induced CYP2A5 catalytic activity was much higher in CYP2E1 KI mice compared to CYP2E1 KO mice, but considering the difference in basal levels of CYP2A5 in the KO and KI mice, the extent of increase in CYP2A5 activity by cadmium was similar (4.5-fold in KO vs 4.1-fold in KI) (Fig 6C). Immunoblot analyses showed that cadmium increased the level of CYP2A5 in both CYP2E1 KI mice and to a less extent in the CYP2E1 KO mice. The treatment with cadmium had no effect on CYP2E1 levels in the KI mice (Fig 6C). Thus, unlike the chronic ethanol treatment, cadmium elevated CYP2A5 under conditions in which it did not alter CYP2E1 activity or content, and cadmium could induce CYP2A5 in the CYP2E1 KO mice.
Discussion

While much of the focus on ethanol induction of CYPs has been on CYP2E1, chronic ethanol consumption can elevate levels of other CYPs such as CYP2B and 3A (Johansson et al, 1988; Niemela et al, 1998). Levels of CYP2E1, 3A and 2A6 were elevated in livers of patients with alcoholic and non-alcoholic liver diseases (Niemela, et al, 2000). Induction of CYP2A5 has been suggested to occur in response to liver injury (Su and Ding, 2004). Results in the current report show that feeding mice an ethanol liquid diet results in an increase in CYP2A5 levels and catalytic activity as compared to pair-fed dextrose controls. Under these conditions, the ethanol feeding produces fatty liver and an increase in triglycerides levels but liver injury is minimal e.g. transaminase levels are increased 2-3-fold, no necroinflammation is observed (Lu et al, 2008b). Ethanol elevated CYP2A5 mRNA levels which likely explain the elevated CYP2A5 protein and activity, however, possible posttranscriptional mechanisms contributing to the elevation of CYP2A5 remain to be evaluated. Ethanol induction of CYP2E1 is mainly posttranscriptional, reflecting stabilization of CYP2E1 against proteosome-mediated degradation (Song et al, 1986; Roberts, 1997; Gonzalez, 2007), although increases in CYP2E1 mRNA can occur at very high blood ethanol levels (Ronis et al, 1993). Ethanol is a ligand and substrate for CYP2E1 which explains its ability to stabilize and increase the half-life of CYP2E1 (Eliasson et al, 1988; Lieber, 1999). Whether ethanol is a ligand and/or substrate for CYP2A5 is currently under investigation.

Whether the increase in CYP2A5 mRNA by ethanol reflects transcriptional activation of the CYP2A5 gene or stabilization of the CYP2A5 mRNA remain to be evaluated. Both mechanisms are possible e.g. pyrazole increases CYP2A5 by a post-transcriptional mechanism involving binding of heterogenous nuclear ribonucleic protein A1 to the 3’-untranslated region of CYP2A5 mRNA (Glisovic et al, 2003). The oxidant-sensitive transcription factor Nrf2 has been shown to regulate the CYP2A5 gene (Abu-Bakar et al, 2004; Abu-Bakar et al, 2007; Lamsa et al, 2010). Two putative stress response elements (STRE) were localized to positions -2514 to -2502 and to -2386 to -2377 of the CYP2A5 promoter with the more
proximal sequence specifically bindings Nrf2 (Abu-Bakar et al, 2007). Pyrazole and heavy metals were ineffective in inducing CYP2A5 in Nrf2 knockout mice (Lu et al, 2008a; Lamsa et al, 2010). Chronic ethanol consumption increases oxidative stress in the liver and elevates Nrf2 mRNA (Gong and Cederbaum, 2006), which may contribute to the ethanol elevation of CYP2A5 mRNA levels. Future assays of nuclear run-on experiments, mRNA stability, CHIP analyses of Nrf2 binding to the CYP2A5 promoter, and whether ethanol induces CYP2A5 in Nrf2 knockout mice would help determine mechanisms by which ethanol elevates CYP2A5 mRNA levels.

We believe the most novel information in this study is the close association between levels of CYP2E1 and CYP2A5 and that the induction of CYP2A5 by ethanol appears to be potentiated by the induction of CYP2E1. Ethanol induction of CYP2A5 was blunted in CYP2E1 KO mice, but restored in CYP2E1 KI mice. Immunohistochemistry staining showed that the distribution of the elevated CYP2E1 and CYP2A5 in the liver produced by the ethanol feeding overlapped. Time course experiments showed that the elevation of CYP2E1 by ethanol occurs prior to the elevation of CYP2A5, perhaps suggesting that elevation of CYP2E1 by ethanol is important for the subsequent induction of CYP2A5. In patients with alcoholic liver disease or cirrhosis of the liver, those samples showing high levels of CYP2E1 also had high levels of CYP2A6 and patients with low levels of CYP2E1 had low levels of CYP2A6. Nrf2 is increased in livers from mice and rats treated with pyrazole and in HepG2 hepatoma cells overexpressing CYP2E1 (Gong and Cederbaum, 2006). These increases may be due to increases in production of reactive oxygen species (ROS) produced by the elevated levels of CYP2E1. Chronic ethanol feeding elevated production of thiobarbituric acid reactive substances, an assay for lipid peroxidation, and lowered GSH levels in the liver of the WT and the CYP2E1 KI mice but not the CYP2E1 KO mice (Lu et al, 2010). Thus, ethanol increased oxidative stress in the WT and the KI mice but not the KO mice. We speculate that ethanol induction of CYP2E1 followed by increases in production of ROS and then activation and translocation of Nrf2 to the nucleus are important steps in the mechanism by which ethanol induces CYP2A5. We are currently studying the effect of antioxidants such as N-acetylcysteine, ascorbate and
alpha-tocopherol on the ethanol induction of CYP2A5, as was done with cadmium induction of CYP2A5 (Fig 6B).

In view of data in the literature that Nrf2 is an important transcription factor for induction of CYP2A5, the role of CYP2E1 in the mechanism by which chronic ethanol induces CYP2A5 is hypothesized to be due to induction of CYP2E1, enhanced ROS production, followed by activation of Nrf2. More surprising is the role of CYP2E1 in contributing to cadmium induction of CYP2A5 under conditions in which cadmium, unlike ethanol, does not elevate CYP2E1. The decline in cadmium induction of CYP2A5 by vitamin c and N-acetylcysteine suggests that ROS plays a role in the induction mechanism. We speculate that both cadmium and CYP2E1 separately produce ROS however the levels of ROS is insufficient for maximal, efficient activation of CYP2A5. Thus, WT mice with high levels of CYP2E1 but without cadmium, or CYP2E1 KO mice without CYP2E1 but with cadmium do not generate sufficient ROS for maximal CYP2A5 induction. However, the combination of cadmium plus CYP2E1 in WT or CYP2E1 KI mice results in sufficient ROS to induce CYP2A5. Hence, basal levels of CYP2E1 are sufficient in combination with cadmium to induce CYP2A5. In the case of chronic ethanol induction, the ethanol elevation of CYP2E1 in the WT or KI mice is necessary to generate sufficient ROS in the absence of cadmium to activate CYP2A5. i.e., basal levels of CYP2E1 are not sufficient. Whether CYP2E1 plays a role in induction of CYP2A5 by other inducers e.g. phenobarbital is not known.

While this study has focused on CYP2A5, chronic ethanol treatment elevated levels of CYP2A4 mRNA. This increase appears to be independent of CYP2E1 since the increase occurs in the CYP2E1 KO mice fed ethanol and the increase was not higher in the CYP2E1 KI mice with higher levels of CYP2E1 than the WT mice. The increase in CYP2A4 does indicate that the CYP2E1 KO mice are responsive to inducers of certain CYP2A family members by ethanol. The mechanism for this CYP2E1-independent ethanol induction of CYP2A4 is currently unknown.
Ethanol induction of CYP2A5 may be of toxicological significance in view of the ability of CYP2A5 to metabolize hepatocarcinogens (Su and Ding, 2004) and drugs such as nicotine (Yamazaki et al, 1999; Benowitz et al, 2006; Zhou et al, 2010). The latter is of special interest since most alcoholics are also smokers (Wall et al, 2007). The possible contribution of CYP2A5 to the metabolic and toxicological effects of ethanol, if any, would be important to evaluate e.g. does CYP2A5, besides CYP2E1, contribute to the increase in ROS production produced by chronic ethanol consumption or to the ethanol-induced fatty liver? Possible approaches to this could be to study the effect of CYP2A5 inhibitors such as 8-methoxysalen, analogous to the use of the CYP2E1 inhibitor chlormethiazole, on ethanol-induced oxidative stress, steatosis, or hepatotoxicity. CYP2A5 knockout mice have recently been developed and used to show that CYP2A5 is the major nicotine and cotinine oxidase in mouse liver (Zhou et al, 2010). It would be very interesting to feed ethanol to CYP2A5 KO mice and assay for parameters such as induction of oxidant stress, liver injury, and steatosis. Is CYP2E1 induced by ethanol in CYP2A5 KO mice? Induction of CYP2A5 by ethanol was decreased in the CYP2E1 KO mice suggesting interaction between these two CYPs. While CYP2E1 has been implicated in some of the toxicological and metabolic effects of ethanol, the possibility that induction of CYP2E1 is permissive for the induction of CYP2A5 may reflect a new contribution of CYP2E1 in the actions of ethanol.
AUTHORSHIP CONTRIBUTIONS

Participated in research design: Lu, Zhuge, and Cederbaum.

Conducted experiments: Lu, Zhuge, and Wu.

Contributed new reagents or analytic tools: Lu, Zhuge, and Wu.

Performed data analysis: Lu, Zhuge, and Cederbaum.

Wrote or contributed to the writing of the manuscript: Lu, Zhuge, and Cederbaum.

Other: Lu and Cederbaum acquired funding for the research.
REFERENCES


Lu Y., Gong P., and Cederbaum A.I. (2008a) Pyrazole induced oxidative liver injury independent of CYP2E1/2A5 induction due to Nrf2 deficiency. Toxicology 252:9-16.


FOOTNESS

These studies were supported by the National Institute of on Alcohol Abuse and Alcoholism, National Institute of Health [grants RO1 AA-017425, AA-018790, P20AA-017067].
LEGENDS to FIGURES

Fig. 1- Western blot analysis for the levels of CYP2A5 and CYP 2E1 in liver homogenates from untreated wild type (WT), CYP2E1 knockout (KO) mice and CYP2E1 knockin (KI) mice. Results from 3 mice in each group are shown. Numbers under the blots refer to the CYP2A5 (lower bands)/β-actin or CYP2E1/β-actin ratio. * P< 0.05 compared to CYP2E1KO group; # P< 0.05 compared to CYP2E1WT group.

Fig. 2- Chronic ethanol administration elevates CYP2A5 levels in SV/129 wild type (WT) mice and CYP2E1 knockin (KI) mice but not in CYP2E1 knockout (KO) mice. WT, KO and KI mice (n=4 in each group) were fed the dextrose or ethanol diets for 3 weeks. A; microsomal oxidation of PNP or coumarin; B; western blots to assay levels of CYP2E1 and CYP2A5; in liver homogenates. C: immunohistochemical staining of liver slices with anti-CYP2E1 or anti-CYP2A5 IgG to detect CYP2E1 or CYP2A5 in intact liver. WD, wild type dextrose control; WE, wild type fed ethanol; KOD, knockouts fed dextrose; KOE, knockouts fed ethanol; KID, knockins fed dextrose; KIE, knockins fed ethanol. * P< 0.05 compared to WD group; # P< 0.05 compared to KID group; & P<0.05 compared to WE group.

Fig. 3- Time course for the induction of CYP2E1 and CYP2A5 by ethanol. SV/129 WT mice (n=4 in each group) were fed the ethanol liquid diet for 0, 1, 2, or 3 weeks. A; western blot analysis for levels of CYP2E1 and CYP2A5 protein; B; PNP oxidation as a reflection of CYP2E1 activity and coumarin 7-hydroxlase activity as a reflection of CYP2A5 activity. Results from mice prior to initiating the ethanol feeding (0 week) are also shown. * P< 0.05 compared with the 0 w CYP2E1; #P<0.05, compared with the 0 w CYP2A5.
Fig. 4- Ethanol elevates CYP2A4 (A) and CYP2A5 mRNA (B) levels. WT, KO and KI mice (n=4 in each group) were fed the dextrose control or the ethanol liquid diet for 3 weeks. Isolated RNA was reverse transcribed to produce cDNA and real-time quantitative PCR assay for the expression of CYP2A5 and CYP2A4 mRNA was carried out as described in Methods. *P < 0.05 compared to WTD group; # P< 0.05 compared to KOD group; & P<0.05 compared to KID group; $ P< 0.05 compared to KOE group; @ P< 0.05 compared to WTE group.

Fig. 5- Levels of CYP2E1 and CYP2A6 (the human ortholog of mouse CYP2A5) in human livers. Western blots were carried out on liver extracts from 2 patients diagnosed with alcoholic liver disease and from 4 patients diagnosed with liver cirrhosis and a control healthy liver. Diagnoses and liver samples were provided by the Department of surgical pathology at Mount Sinai.

Fig. 6- Induction of CYP2A5 by cadmium in WT, CYP2E1 KO and CYP2E1 KI mice. Mice were injected IP with 3 mg/kg cadmium chloride or saline as control, and 18 h later, mice were sacrificed. PNP oxidation as a reflection of CYP2E1 activity and coumarin 7-hydroxylase activity as a reflection of CYP2A5 activity were determined or levels of CYP2E1 or CYP2A5 determined by immunoblots. A; CYP2A5 but not CYP2E1 was induced by cadmium in female and male WT mice (n=3 in each group). *P < 0.05 compared to Male Cont group; # P< 0.05 compared to Female Cont group; $ P<0.05 compared to Male Cd group. Cd, cadmium. B; Vc and NAC blocked cadmium induction of CYP2A5 in WT mice. WT mice were pretreated with saline (n=3) or Vc (n=3) or NAC (n=3) before cadmium treatment as described in Materials and Methods. Controls received saline IP (n=4). Catalytic activities and Western Blot are shown. *P < 0.05 compared to Control group; # P< 0.05 compared to Cd group. Cd, cadmium. C; Induction of CYP2A5 by cadmium in female CYP2E1 KO and CYP2E1 KI mice (n=4 in each group). Treatments are identical to the female WT mice in A. Catalytic activities and Western Blot are...
shown. *P < 0.05 compared to KO Cont group; # P < 0.05 compared to KI Cont group; $ P < 0.05 compared to KO Cd group. Cd, cadmium.
**Figure 1**

[Image of a gel electrophoresis showing bands for CYP2E1 KO, CYP2E1 WT, and CYP2E1 KI with corresponding molecular weights: 1 ±0.05, 2.1 ±0.06*, and 3.0 ±0.36* #. Below, bands for CYP2E1 with molecular weights: 1 ±0.03, and 3.25 ±0.43 #. Beside, bands for β-actin with a molecular weight of 1 ±0.05.]
Figure 2

CYP2E1/2A5 relative activity (fold)

WD WE KOD KOE KIE

* CYP2A5  CYP2E1

# &

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 2

Table:

<table>
<thead>
<tr>
<th>WD</th>
<th>WE</th>
<th>KOD</th>
<th>KOE</th>
<th>KID</th>
<th>KIE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1±0.05</td>
<td>4.4±0.37*</td>
<td>2.7±0.44</td>
<td>23.3±3.7*</td>
<td>1±0.05</td>
<td>2.4±0.07*</td>
</tr>
</tbody>
</table>

* Indicates significant difference.

β-actin

CYP2A5

CYP2E1

This article has not been copyedited and formatted. The final version may differ from this version.
Figure 3

A

0 w  1 w  2 w  3 w
CYP2E1
CYP2A5
β-actin

B

CYP2E1/2A5 activity (fold)

0  1  2  3  4  5

CYP2E1

CYP2A5

0w  1w  2w  3w

*  #

Figure 3
Figure 4
Figure 5

Normal  ALD  Cirrhosis

CYP2E1

CYP2A6

β-actin

This article has not been copyedited and formatted. The final version may differ from this version.

DMD Fast Forward. Published on November 4, 2010 as DOI: 10.1124/dmd.110.035691

Downloaded from dmd.aspetjournals.org on October 12, 2023.
Figure 6

**Panel A**
- Graph showing CYP2E1/2A5 activity (fold) for Male Cont, Male Cd, Female Cont, and Female Cd.
- CYP2A5 and CYP2E1 activity levels are compared.
- Significant differences indicated by asterisks (*) and hash symbols (#).

**Panel B**
- Graph showing CYP2A5 and CYP2E1 activity (fold) for Control, Cd, Cd+Vc, Cd+NAC.
- β-actin loading control shown below the activity graph.
- Significant differences indicated by asterisks (*) and hash symbols (#).

This article has not been copyedited and formatted. The final version may differ from this version.
**Figure 6**

CYP2E1/2A5 activity (fold)

<table>
<thead>
<tr>
<th>Condition</th>
<th>CYP2A5</th>
<th>CYP2E1</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO Cont</td>
<td>1 ± 0.05</td>
<td>1.0 ± 0.15</td>
</tr>
<tr>
<td>KO Cd</td>
<td>1.8 ± 0.27 *</td>
<td>2.1 ± 0.21 *</td>
</tr>
<tr>
<td>KI Cont</td>
<td>2.1 ± 0.21 *</td>
<td>4.3 ± 0.3 # $</td>
</tr>
<tr>
<td>KI Cd</td>
<td>*</td>
<td># $</td>
</tr>
</tbody>
</table>

*Significant differences compared to control.

#Significant differences compared to KO Cd.

$Significant differences compared to KI Cont.

β-actin

Graph showing the activity of CYP2E1 and CYP2A5 in different conditions.